Pharma

The Readout Meghana Keshavan

STAT Plus: Vanda Pharmaceuticals has another suitor

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Jason Mast

STAT Plus: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, the GSK-Elsie deal, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the aftermath of FDA vote on MDMA, rising pharma layoffs, and more

The Readout Elaine Chen

Novavax will be able to supply Covid-19 vaccines this fall

Pharma Meghana Keshavan

STAT Plus: Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more

The Readout Jason Mast

STAT Plus: Testing begins for a new form of PrEP

Pharmalot Ed Silverman

STAT Plus: Student group that ranked med schools over industry conflicts votes to accept pharma funding

Pharmalot Ed Silverman

STAT Plus: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

Pharmalot Ed Silverman

STAT Plus: U.S. drug shortages have reached a decade high and are lasting longer, too

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more

Pharma Olivia Goldhill and Meghana Keshavan

STAT Plus: FDA advisory panel votes overwhelmingly against MDMA therapy for PTSD

Pharmalot Ed Silverman

STAT Plus: Leading CRO to pay record fine for badly neglecting hundreds of beagles in breeding facility

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth

Pharma Matthew Herper

STAT Plus: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer

Biotech Adam Feuerstein

STAT Plus: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment

Pharma Andrew Joseph

STAT Plus: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug

Pharma Angus Chen

STAT Plus: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers

Biotech Elaine Chen

STAT Plus: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

Pharmalot Ed Silverman

STAT Plus: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program